Year archive

Moberg Pharma — 2024 filings

All 62 regulatory filings released by Moberg Pharma (MOB) in 2024, sourced directly from the official regulator.

62 Filings

2024 Period

2024 filings (62)

Filing	Released	Lang
Ny terbinafin-leverantör säkerställd Regulatory Filings	2024-12-18	Swedish
New terbinafine supplier secured Regulatory Filings	2024-12-18	English
Moberg Pharma rapporterar topline-data i den nordamerikanska fas 3-studien och får tillbaka rättigheter för MOB-015 i EU Earnings Release Q4 2024	2024-12-10	Swedish
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU Legal Proceedings Report	2024-12-10	English
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-11-12	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-11-12	English
Moberg Pharma’s Nomination Committee appointed Regulatory Filings	2024-11-08	English
Moberg Pharmas valberedning utsedd Board/Management Information	2024-11-08	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-10-28	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-10-22	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-10-10	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-10-01	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-09-27	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-09-24	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-09-18	English
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients Earnings Release Q3 2024	2024-09-13	English
Moberg Pharma sänker förväntningarna på primärt behandlingsmål i pågående fas 3-studie baserat på en delmängd av data Legal Proceedings Report	2024-09-13	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report H1 2024	2024-08-13	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report H1 2024	2024-08-13	English
New number of shares and votes in Moberg Pharma AB (publ) Declaration of Voting Results & Voting Rights Announcements	2024-07-31	English
Förändring av antalet aktier och röster i Moberg Pharma AB (publ) Declaration of Voting Results & Voting Rights Announcements	2024-07-31	Swedish
Declaration of Voting Results & Voting Rights Announcements 2024 Declaration of Voting Results & Voting Rights Announcements	2024-07-10	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-07-03	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-06-28	English
New number of shares and votes in Moberg Pharma AB (publ) Declaration of Voting Results & Voting Rights Announcements	2024-06-28	English
Förändring av antalet aktier och röster i Moberg Pharma AB (publ) Declaration of Voting Results & Voting Rights Announcements	2024-06-28	Swedish
Moberg Pharma tillförs 336 MSEK genom TO 2 och riktad nyemission till toppgaranter – teckningsgraden i TO 2 blev 98% Capital/Financing Update	2024-06-24	Swedish
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors – subscription rate in TO 2 of 98% Capital/Financing Update	2024-06-24	English
The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024 Share Issue/Capital Change	2024-06-17	English
Sista dag för handel i Moberg Pharmas teckningsoptioner av serie 2023:1 (TO 2) är idag, den 17 juni 2024 Share Issue/Capital Change	2024-06-17	Swedish
Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge Capital/Financing Update	2024-06-11	English
Moberg Pharma har säkerställt nyttjande av teckningsoptioner och ingått vederlagsfri toppgaranti Capital/Financing Update	2024-06-11	Swedish
Idag inleds nyttjandeperioden för Moberg Pharmas teckningsoptioner av serie 2023:1 (TO 2) Capital/Financing Update	2024-06-05	Swedish
The exercise period for Moberg Pharma's warrants of series 2023:1 (TO 2) begins today Capital/Financing Update	2024-06-05	English
Subscription price for Moberg Pharma's warrants of series 2023:1 (TO 2) determined Share Issue/Capital Change	2024-05-31	English
Teckningskurs fastställd för Moberg Pharmas teckningsoptioner av serie 2023:1 TO 2 Capital/Financing Update	2024-05-31	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-05-22	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-05-20	English
Kommuniké från Moberg Pharmas årsstämma den 14 maj 2024 AGM Information	2024-05-14	Swedish
Bulletin from Moberg Pharma’s AGM on May 14[th], 2024 AGM Information	2024-05-14	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-05-08	English
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-07	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-07	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-17	English
Declaration of Voting Results & Voting Rights Announcements 2024 Declaration of Voting Results & Voting Rights Announcements	2024-04-16	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-15	English
Notice of Annual General Meeting in Moberg Pharma AB (publ) AGM Information	2024-04-12	English
Kallelse till årsstämma i Moberg Pharma AB (publ) AGM Information	2024-04-12	Swedish
Annual Report (ESEF) 2023 Annual Report (ESEF) FY 2023	2024-04-12	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-11	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-10	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-04-04	English
Declaration of Voting Results & Voting Rights Announcements 2024 Declaration of Voting Results & Voting Rights Announcements	2024-04-03	English
Declaration of Voting Results & Voting Rights Announcements 2024 Declaration of Voting Results & Voting Rights Announcements	2024-03-28	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-03-27	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-03-25	English
Valberedningens förslag till årsstämman 2024 AGM Information	2024-02-19	Swedish
The Nomination Committee’s proposal to the Annual General Meeting 2024 AGM Information	2024-02-19	English
Earnings Release 2023 Earnings Release FY 2023	2024-02-13	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report FY 2023	2024-02-13	English
MOB-015 is launched in Sweden under the brand name Terclara– pharmacies report major demand for the new medication Regulatory Filings	2024-02-07	English
MOB-015 lanseras i Sverige under varumärket Terclara– stor efterfrågan hos apoteken för det nya läkemedlet mot nagelsvamp Regulatory Filings	2024-02-07	Swedish

Filings by year

2026 11 filings
2025 36 filings
2024 62 filings
2023 56 filings
2022 40 filings
2021 39 filings
2020 62 filings
2019 83 filings
2018 53 filings
2017 44 filings
2016 70 filings
2015 55 filings
2014 48 filings
2013 51 filings
2012 56 filings
2011 16 filings